Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

Claim 1 (currently amended) A method for the treatment ~~or prevention~~ of conditions or diseases of the gastrointestinal tract involving an overproduction of nitric oxide (NO) by inducible nitric oxide synthase (iNOS), in a subject in need of such treatment or prevention, said method comprising administering to the subject an anti-inflammatory effective amount of an inducible nitric oxide synthase selective inhibitor or pharmaceutically acceptable salt thereof or prodrug thereof, wherein the inducible nitric oxide synthase inhibitor is ~~selected from the group consisting of:~~

~~a compound having Formula I~~



~~I~~

~~wherein:~~

~~R^1 is selected from the group consisting of H, halo and alkyl which may be optionally substituted by one or more halo;~~

~~R^2 is selected from the group consisting of H, halo and alkyl which may be optionally substituted by one or more halo;~~

~~with the proviso that at least one of R^1 or R^2 contains a halo;~~

~~R^7 is selected from the group consisting of H and hydroxy;~~

~~J is selected from the group consisting of hydroxy, alkoxy, and NR^3R^4 wherein;~~

~~R^3 is selected from the group consisting of H, lower alkyl, lower alkylenyl and lower alkynyl;~~

~~R^4 is selected from the group consisting of H, and a heterocyclic ring in which at least one member of the ring is carbon and in which 1 to about 4 heteroatoms are independently selected from oxygen, nitrogen and sulfur and said heterocyclic ring may be optionally substituted with heteroarylamino, N-aryl-N-alkylamino, N-heteroarylamino-N-alkylamino, haloalkylthio, alkanoyloxy, alkoxy, heteroaralkoxy, cycloalkoxy, cycloalkenyloxy, hydroxy, amino, thio, nitro, lower alkylamino, alkylthio, alkylthioalkyl, arylamino, aralkylamino, arylthio, alkylsulfinyl, alkylsulfonyl, alkylsulfonamido, alkylaminosulfonyl, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, monoarylamidosulfonyl, arylsulfonamido, diarylamidosulfonyl, monoalkyl monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkenyl, lower cycloalkylalkyl, lower cycloalkenylalkyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyaralkyl, hydroxyalkyl, hydoxyheteroaralkyl, haloalkoxyalkyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, cyanoalkyl, dicyanoalkyl, carboxamidoalkyl, dicarboxamidoalkyl, cyanocarboalkoxyalkyl, carboalkoxyalkyl, dicarboalkoxyalkyl, cyanocycloalkyl, dicyanocycloalkyl, carboxamidocycloalkyl, dicarboxamidocycloalkyl, carboalkoxycyanocycloalkyl, carboalkoxycycloalkyl, dicarboalkoxycycloalkyl, formylalkyl, acylalkyl, dialkoxyphosphonoalkyl, diaralkoxyphosphonoalkyl, phosphonoalkyl,~~

~~dialkoxyphosphonoalkoxy, diaralkoxyphosphonoalkoxy, phosphonoalkoxy, dialkoxyphosphonoalkylamino, diaralkoxyphosphonoalkylamino, phosphonoalkylamino, dialkoxyphosphonoalkyl, diaralkoxyphosphonoalkyl, guanidino, amidino, and acylamino;~~

a compound having a structure corresponding to Formula **II**



II

wherein X is selected from the group consisting of -S-, -S(O)-, and -$S(O)_2$-, R^{12} is selected from the group consisting of C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_5 alkoxy-C_1 alkyl, and C_1-C_5 alkylthio-C_1 alkyl wherein each of these groups is optionally substituted by one or more substituent selected from the group consisting of -OH, alkoxy, and halogen, R^{18} is selected from the group consisting of $-OR^{24}$ and -$N(R^{25})(R^{26})$, and R^{13} is selected from the group consisting of -H, -OH, -C(O)-R^{27}, -C(O)-O-R^{28}, and -C(O)-S-R^{29}; or R^{18} is -$N(R^{30})$-, and R^{13} is -C(O)-, wherein R^{18} and R^{13} together with the atoms to which they are attached form a ring; or R^{18} is -O-, and R^{13} is -$C(R^{31})(R^{32})$-, wherein R^{18} and R^{13} together with the atoms to which they are attached form a ring, wherein if R^{13} is -$C(R3^{21})(R^{32})$-, then R^{14} is -C(O)-O-R^{33}; otherwise R^{14} is –H, R^{11}, R^{15}, R^{16}, and R^{17} independently are selected from the group consisting of -H, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, and C_1-C_5 alkoxy-C_1 alkyl, R^{19} and R^{20} independently are selected from the group consisting of -H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, and C_1-C_5 alkoxy-C_1 alkyl, R^{21} is selected from the group

consisting of -H, -OH, -C(O)-O-R^{34}, and -C(O)-S-R^{35}, and R^{22} is selected from the group consisting of -H, -OH, -C(O)-O-R^{36}, and -C(O)-S-R^{37}; or R^{21} is -O-, and R^{22} is -C(O)-, wherein R^{21} and R^{22} together with the atoms to which they are attached form a ring; or R^{21} is -C(O)-, and R^{22} is -O-, wherein R^{21} and R^{22} together with the atoms to which they are attached form a ring, R^{23} is C_1 alkyl, R^{24} is selected from the group consisting of -H and C_1-C_6 alkyl, wherein when R^{24} is C_1-C_6 alkyl, R^{24} is optionally substituted by one or more moieties selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl, R^{25} is selected from the group consisting of -H, alkyl, and alkoxy, and R^{26} is selected from the group consisting of -H, -OH, alkyl, alkoxy, -C(O)-R^{38}, -C(O)-O-R^{39}, and -C(O)-S-R^{40}; wherein when R^{25} and R^{26} independently are alkyl or alkoxy, R^{25} and R^{26} independently are optionally substituted with one or more moieties selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl; or R^{25} is -H; and R^{26} is selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl, R^{27}, R^{28}, R^{29}, R^{30}, R^{31}, R^{32}, R^{33}, R^{34}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, and R^{40} independently are selected from the group consisting of -H and alkyl, wherein alkyl is optionally substituted by one or more moieties selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein when any of R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, $R19^{9}$, R^{20}, R^{21}, R^{22}, R^{23}, R^{24}, R^{25}, R^{26}, R^{27}, R^{28}, R^{29}, R^{30}, R^{31}, R^{32}, R^{33}, R^{34}, R^{35} R^{36}, R^{37}, R^{38}, R^{39}, and R^{40} independently is a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclyl, aryl, and heteroaryl, then the moiety is optionally substituted by one or more substituent selected from the group consisting of -OH, alkoxy, and halogen;

and wherein the compound is selected from the group consisting of:



S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine, dihydrochloride;



2-[[[2-[(1-Iminoethyl)amino]ethyl]thio]methyl]-*O*-methyl-D-serine, dihydrochloride;



S-[2-[(1-Iminoethyl)amino]ethyl]-2-ethyl-L-cysteine, dihydrochloride;



2-[[[[2-(1-Iminoethyl)amino]ethyl]thio]methyl]-D-valine, dihydrochloride;



2TFA

S-[2-(1-Iminoethylamino)ethyl]-2-methyl-(D/L)-cysteine, bistrifluoroacetate;



2HCl

(2*R*)-2-Amino-3[[2-[(1-iminoethyl)amino]ethyl]sulfinyl]-2-methylpropanoic acid, dihydrochloride; and



2HCl

(2*R*)-2-Amino-3[[2-[(1-iminoethyl)amino]ethyl]sulfonyl]-2-methylpropanoic acid dihydrochloride,

~~a compound represented by Formula III~~



III

~~wherein:~~

~~R^{41} is H or methyl; and~~

~~R^{42} is H or methyl;~~

~~a compound of formula IV~~



~~IV;~~

~~a compound of Formula V:~~



~~V~~

~~wherein:~~

~~R^{43} is selected from the group consisting of hydrogen, halo, C_1-C_5 alkyl and C_1-C_5 alkyl substituted by alkoxy or one or more halo;~~

~~R^{44} is selected from the group consisting of hydrogen, halo, C_1-C_5 alkyl and C_1-C_5 alkyl substituted by alkoxy or one or more halo;~~

~~R^{45} is C_1-C_5 alkyl or C_1-C_5 alkyl be substituted by alkoxy or one or more halo;~~

~~a compound of Formula VI:~~



~~VI~~

~~wherein:~~

~~R^{46} is C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo;~~

~~a compound of Formula VII~~



~~VII~~

~~wherein:~~

~~R^{47} is selected from the group consisting of hydrogen, halo, C_1-C_5 alkyl and C_1-C_5 alkyl substituted by alkoxy or one or more halo;~~

~~R^{48} is selected from the group consisting of hydrogen, halo, C_1-C_5 alkyl and C_1-C_5 alkyl substituted by alkoxy or one or more halo;~~

~~R^{49} is C_1-C_5 alkyl or C_1-C_5 alkyl be substituted by alkoxy or one or more halo;~~

~~a compound of Formula VIII~~



~~VIII~~

~~wherein:~~

~~R^{50} is C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo;~~

~~a compound of formula **IX**~~



~~**IX**~~

~~wherein:~~

~~R^{50} is selected from the group consisting of hydrogen, halo, and C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo;~~

~~R^{51} is selected from the group consisting of hydrogen, halo, and C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo;~~

~~R^{52} is C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo;~~

~~R^{53} is selected from the group consisting of hydrogen, halo, andC_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo; and~~

~~R^{54} is selected from the group consisting of halo and C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo;~~

~~a compound of formula **X**~~



~~X~~

~~wherein:~~

~~R^{55} is C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo.~~

~~*a compound having the formula XI*~~.



~~2S-amino-6-[(1-iminoethyl)amino]-N-(1H-tetrazol-5-yl) hexanamide, hydrate, dihydrochloride~~

~~XI~~

~~A compound of formula XII:~~



~~XII~~

~~wherein R^{79} is selected from C_{1-4} alkyl, C_{3-4} cycloalkyl, C_{1-4} hydroxyalkyl, and C_{1-4} haloalkyl;~~

~~a compound of Formula XIII, Formula XIV or Formula XV:~~



~~Formula XIII;~~



~~Formula XIV; or~~



~~Formula XV;~~

~~wherein:~~

~~A is $-R^{56}$, $-OR^{56}$, $-C(O)N(R^{56})R^{57}$, $-P(O)[N(R^{56})R^{57}]_2$, $-N(R^{56})C(O)R^{57}$, $-N(R^{76})C(O)OR^{56}$, $-N(R^{56})R^{76}$, $-N(R^{71})C(O)N(R^{56})R^{71}$, $-S(O)_tR^{56}$, $-SO_2NHC(O)R^{56}$, $-NHSO_2R^{77}$, $-SO_2NH(R^{56})H$, $-C(O)NHSO_2R^{77}$, and $-CH=NOR^{56}$;~~

~~each X, Y and Z are independently N or $C(R^{19})$;~~

~~each U is N or $C(R^{60})$, provided that U is N only when X is N and Z and Y are CR^{74};~~

~~V is $N(R^{59})$, S, O or $C(R^{59})H$;~~

~~Each W is N or CH;~~

~~Q is chosen from the group consisting of a direct bond, $-C(O)-$, $-O-$, $-C(=N-R^{56})-$, $S(O)_t$, and $-N(R^{61})-$;~~

~~m is zero or an integer from 1 to 4;~~

~~n is zero or an integer from 1 to 3;~~

~~q is zero or one;~~

~~r is zero or one, provided that when Q and V are heteroatoms, m, q, and r cannot all be zero;~~

~~when A is $-OR^{56}$, $N(R^{56})C(O)R^{57}$, $-N(R^{71})C(O)OR^{57}$, $-N(R^{56})R^{76}$, $-N(R^{71})C(O)N(R^{56})R^{71}$, $-S(O)_tR^{56}$ (where t is zero), or $-NHSO_2R^{77}$, n, q, and r~~

~~cannot all be zero; and when Q is a heteroatom and A is $-OR^{56}$, $-N(R^{56})C(O)R^{57}$, $-N(R^{71})C(O)OR^{57}$, $-N(R^{56})R^{76}$, $-N(R^{71})C(O)N(R^{56})R^{71}$, $-S(O)_tR^{56}$ (when t is zero), or $-NHSO_2R^{77}$, m and n cannot both be zero;~~

~~t is zero, one or two;~~



~~is an optionally substituted N-heterocyclyl;~~



~~is an optionally substituted carbocyclyl or optionally substituted N-heterocyclyl;~~

~~each R^{56} and R^{57} are independently chosen from the group consisting of hydrogen, optionally substituted C_1-C_{20} alkyl, optionally substituted cycloalkyl, $-[C_0$-C_8 alkyl$]-R^{64}$, $-[C_2$-C_8 alkenyl$]-R^{64}$, $-[C_2$-C_8 alkynyl$]-R^{64}$, $-[C_2$-C_8 alkyl$]-R^{65}$ (optionally substituted by hydroxy), $-[C_1$-$C_8]-R^{66}$ (optionally substituted by hydroxy), optionally substituted heterocyclyl;~~

~~or R^{56} and R^{57} together with the nitrogen atom to which they are attached is an optionally substituted N-heterocyclyl;~~

~~R^{58} is chosen from the group consisting of hydrogen, alkyl, cycloalkyl, optionally substituted aryl, haloalkyl, $-[C_1$-C_8 alkyl$]-C(O)N(R^{56})R^{57}$, $-[C_1$-C_8 alkyl$]-N(R^{56})R^{57}$, $-[C_1$-C_8 alkyl$]-R^{63}$, $-[C_2$-C_8 alk2yl$]-R^{65}$, $-[C_1$-C_8 alkyl$]-R^{66}$, and heterocyclyl (optionally substituted by one or more substitutents selected from the group consisting of halo, alkyl, alkoxy and imidazolyl);~~

~~or when Q is $-N(R^{58})-$ or a direct bond to R^{58}, R^{58} may additionally be aminocarbonyl, alkoxycarbonyl, alkylsulfonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl and $-C(=NR^{73})-NH_2$;~~

~~or -Q-R^{58} taken together represents -C(O)OH, -C(O)N(R^{56})R^{57} or~~



~~R^{59} is chosen from the group consisting of hydrogen, alkyl, aryl, aralkyl and cycloalkyl;~~

~~Provided that when A is -R^{56} or -OR^{56}, R^{59} cannot be hydrogen, and when V is CH, R^{59} may additionally be hydroxy;~~

~~R^{60} is chosen from the group consisting of hydrogen, alkyl, aryl, aralkyl, haloalkyl, optionally substituted aralkyl, optionally substituted aryl, -OR^{71}, -$S(O)_t$-R^{71}, N(R^{71})R^{76}, N(R^{71})C(O)N(R^{56})R^{71}, N(R^{71})C(O)OR^{71}, N(R^{71})C(O)-R^{71}, -[C_0-C_8-alkyl]-C(H)[C(O)R^{71}]$_2$ and -[C_0-C_8-alkyl]-C(O)N(R^{56})R^{71};~~

~~R^{61} is chosen from the group consisting of hydrogen, alkyl, cycloalkyl, -[C_1-C_8-alkyl]-R^{63}, -[C_2-C_8]alkyl]-R^{65}, -[C_1-C_8-alkyl]-R^{66}, acyl, -C(O)R^{63}, -C(O)-[C_1-C_8-alkyl]-R^{63}, alkoxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted aralkoxycarbonyl, alkylsulfonyl, optionally substituted aryl, optionally substituted heterocyclyl, alkoxycarbonylalkyl, carboxyalkyl, optionally substituted arylsulfonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, optionally substituted arylaminocarbonyl, aminosulfonyl, monoalkylaminosulfonyl dialkylaminosulfonyl, arylaminosulfonyl, arylsulfonylaminocarbonyl, optionally substituted N-heterocyclyl, -C(=NH)-N(CN)R^{56}, -C(O)R^{78}-N(R^{56})R^{57}, -C(O)-N(R^{56})R^{78}-C(O)OR^{56};~~

~~each R^{63} and R^{64} are independently chosen from the group consisting of haloalkyl,~~

~~cycloalkyl, (optionally substituted with halo, cyano, alkyl or alkoxy), carbocyclyl (optionally substituted with one or more substituents selected from the group~~

~~consisting of halo, alkyl and alkoxy) and heterocyclyl (optionally substituted with alkyl, aralkyl or alkoxy);~~

~~each R^{65} is independently chosen from the group consisting of halo, alkoxy, optionally substituted aryloxy, optionally substituted aralkoxy, optionally substituted $-S(O)_t-R^{77}$, acylamino, amino, monoalkylamino, dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto, alkylsulfonamido;~~

~~each R^{66} is independently chosen from the group consisting of cyano, di(alkoxy)alkyl, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl and dialkylaminocarbonyl;~~

~~each R^{67}, R^{68}, R^{69}, R^{70}, R^{72}, and R^{75} are independently hydrogen or alkyl;~~

~~each R^{71} is independently hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl or cycloalkyl;~~

~~R^{73} is hydrogen, NO_2, or toluenesulfonyl;~~

~~each R^{74} is independently hydrogen, alkyl (optionally substituted with hydroxy), cyclopropyl, halo or haloalkyl;~~

~~each R^{76} is independently hydrogen, alkyl, cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, $-C(O)R^{77}$ or $-SO_2R^{77}$;~~

~~or R^{76} taken together with R^{56} and the nitrogen to which they are attached is an optionally substituted N-heterocyclyl;~~

~~or R^{76} taken together with R^{71} and the nitrogen to which they are attached is an optionally substituted N-heterocyclyl;~~

~~each R^{77} is independently alkyl, cycloalkyl, optionally substituted aryl or optionally substituted aralkyl; and~~

~~R^{78} is an amino acid residue; and~~

~~PPA250~~



~~PPA250~~

or a pharmaceutically acceptable salt or prodrug of any of said inducible nitric oxide synthase inhibitors.

Claim 2 (original) The method of claim 1 wherein the condition or disease of the gastrointestinal tract is selected from the group consisting of inflammatory bowel disease, Crohn's disease, ulcerative colitis, peptic ulcer disease, gastric ulceration, duodenal ulceration, gastritis, ileitis, gastroesophageal reflux disease, irritable bowel syndrome, paralytic ileus and diarrhea.

Claim 3 (original) The method of claim 1 wherein the condition or disease of the gastrointestinal tract is inflammatory bowel disease.

Claim 4 (original) The method of claim 1 wherein the condition or disease of the gastrointestinal tract is Crohn's disease.

Claim 5 (original) The method of claim 1 wherein the condition or disease of the gastrointestinal tract is ulcerative colitis.

Claim 6 (original) The method of claim 1 wherein the condition or disease of the gastrointestinal tract is gastritis.

Claim 7 (original) The method of claim 1 wherein the condition or disease of the gastrointestinal tract is ileitis.

Claim 8 (original) The method of claim 1 wherein the condition or disease of the gastrointestinal tract is peptic ulceration.

Claim 9 (original) The method of claim 8 wherein the condition or disease of the gastrointestinal tract is gastric ulceration.

Claim 10 (original) The method of claim 8 wherein the condition or disease of the gastrointestinal tract is duodenal ulceration.

Claim 11 (original) The method of claim 1 wherein the condition or disease of the gastrointestinal tract is esophagitis.

Claim 12 (original) The method of claim 1 wherein the condition or disease of the gastrointestinal tract is gastroesophageal reflux disease.

Claim 13 (original) The method of claim 1 wherein the condition or disease of the gastrointestinal tract is irritable bowel syndrome.

Claim 14 (original) The method of Claim 1 wherein the condition or disease of the gastrointestinal tract is selected from group consisting of peptic ulcer disease and gastritis, said method further comprising administering to the subject an amount of an antimicrobial compound or pharmaceutically acceptable salt thereof or prodrug thereof, wherein the amount of the inducible nitric oxide synthase selective inhibitor and the amount of the antimicrobial compound together constitute an amount effective against the condition or disease of the gastrointestinal tract.

Claim 15 (original) The method of Claim 14 wherein the antimicrobial compound comprises an antibiotic compound.

Claim 16 (original) The method of Claim 14 wherein the antimicrobial compound comprises at least one compound selected from the group consisting of the following: amoxicillin, clarithromycin, rifabutin, bismuth subsalicylate, metronidazole, and tetracycline.

Claim 17 (original) The method of Claim 1 further comprising administering to the subject an amount of an antisecretory compound or pharmaceutically acceptable salt thereof or prodrug thereof, wherein the amount of the inducible nitric oxide synthase selective inhibitor and the amount of the antisecretory compound together constitute an amount effective against the condition or disease of the gastrointestinal tract.1

Claim 18 (original) The method of Claim 17 wherein the antisecretory compound comprises a proton-pump inhibitor.

Claim 19 (original) The method of Claim 17 wherein the antisecretory compound comprises omeprazole.

Claim 20 (original) The method of Claim 17 wherein the antisecretory compound comprises an H_2-receptor anatagonist.

Claim 21 (original) The method of Claim 20 wherein the antisecretory compound comprises ranitidine.

Claim 22. (currently amended) A method for the treatment ~~or prevention~~ of inflammatory conditions or diseases of the gastrointestinal tract involving an overproduction of nitric oxide (NO) by inducible nitric oxide synthase (iNOS) and microbial infection, in a subject in need of such treatment or prevention, said method comprising administering to the subject an amount of an inducible nitric oxide synthase selective inhibitor or pharmaceutically acceptable salt thereof or prodrug thereof, and an amount of an antimicrobial compound or pharmaceutically acceptable salt thereof or prodrug thereof, wherein the amount of the inducible nitric oxide synthase selective inhibitor and the amount of the antibiotic compound together constitute an amount effective against the condition or disease of the gastrointestinal tract, wherein the inducible nitric oxide synthase inhibitor is ~~selected from the group consisting of:~~

~~a compound having Formula I~~



~~wherein:~~

~~R^1 is selected from the group consisting of H, halo and alkyl which may be optionally substituted by one or more halo;~~

~~R^2 is selected from the group consisting of H, halo and alkyl which may be optionally substituted by one or more halo;~~

~~with the proviso that at least one of R^1 or R^2 contains a halo;~~

~~R^7 is selected from the group consisting of H and hydroxy;~~

~~J is selected from the group consisting of hydroxy, alkoxy, and NR^3R^4 wherein;~~

~~R^3 is selected from the group consisting of H, lower alkyl, lower alkylenyl and lower alkynyl;~~

~~R^4 is selected from the group consisting of H, and a heterocyclic ring in which at least one member of the ring is carbon and in which 1 to about 4 heteroatoms are independently selected from oxygen, nitrogen and sulfur and said heterocyclic ring may be optionally substituted with heteroarylamino, N-aryl-N-alkylamino, N-heteroarylamino-N-alkylamino, haloalkylthio, alkanoyloxy, alkoxy, heteroaralkoxy, cycloalkoxy, cycloalkenyloxy, hydroxy, amino, thio, nitro, lower alkylamino, alkylthio, alkylthioalkyl, arylamino, aralkylamino, arylthio, alkylsulfinyl, alkylsulfonyl, alkylsulfonamido, alkylaminosulfonyl, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, monoarylamidosulfonyl, arylsulfonamido, diarylamidosulfonyl, monoalkyl monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio, heteroarylsulfinyl,~~

~~heteroarylsulfonyl, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkenyl, lower cycloalkylalkyl, lower cycloalkenylalkyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyaralkyl, hydroxyalkyl, hydoxyheteroaralkyl, haloalkoxyalkyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, cyanoalkyl, dicyanoalkyl, carboxamidoalkyl, dicarboxamidoalkyl, cyanocarboalkoxyalkyl, carboalkoxyalkyl, dicarboalkoxyalkyl, cyanocycloalkyl, dicyanocycloalkyl, carboxamidocycloalkyl, dicarboxamidocycloalkyl, carboalkoxycyanocycloalkyl, carboalkoxycycloalkyl, dicarboalkoxycycloalkyl, formylalkyl, acylalkyl, dialkoxyphosphonoalkyl, diaralkoxyphosphonoalkyl, phosphonoalkyl, dialkoxyphosphonoalkoxy, diaralkoxyphosphonoalkoxy, phosphonoalkoxy, dialkoxyphosphonoalkylamino, diaralkoxyphosphonoalkylamino, phosphonoalkylamino, dialkoxyphosphonoalkyl, diaralkoxyphosphonoalkyl, guanidino, amidino, and acylamino;~~

a compound having a structure corresponding to Formula II



II

wherein X is selected from the group consisting of -S-, -S(O)-, and -$S(O)_2$-, R^{12} is selected from the group consisting of C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_5 alkoxy-C_1 alkyl, and C_1-C_5 alkylthio-C_1 alkyl wherein each of these groups is optionally substituted by one or more substituent selected from the group consisting of -OH, alkoxy, and halogen, R^{18} is selected from the group consisting of $-OR^{24}$ and -$N(R^{25})(R^{26})$, and R^{13} is selected from the group consisting of -H, -OH, -C(O)-R^{27}, -C(O)-O-R^{28}, and -C(O)-S-R^{29}; or R^{18} is -$N(R^{30})$-, and R^{13} is -C(O)-, wherein R^{18} and R^{13} together with the atoms to which they are attached form a ring; or R^{18} is -O-, and R^{13} is -$C(R^{31})(R^{32})$-, wherein R^{18} and R^{13} together with the atoms to which they are attached form a ring, wherein if R^{13} is -$C(R3^{21})(R^{32})$-, then R^{14} is -C(O)-O-R^{33}; otherwise R^{14} is –H, R^{11}, R^{15}, R^{16}, and R^{17} independently are selected from the group consisting of -H, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, and C_1-C_5 alkoxy-C_1 alkyl, R^{19} and R^{20} independently are selected from the group consisting of -H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, and C_1-C_5 alkoxy-C_1 alkyl, R^{21} is selected from the group consisting of -H, -OH, -C(O)-O-R^{34}, and -C(O)-S-R^{35}, and R^{22} is selected from the group consisting of -H, -OH, -C(O)-O-R^{36}, and -C(O)-S-R^{37}; or R^{21} is -O-, and R^{22} is -C(O)-, wherein R^{21} and R^{22} together with the atoms to which they are attached form a ring; or R^{21} is -C(O)-, and R^{22} is -O-, wherein R^{21} and R^{22} together with the atoms to which they are attached form a ring, R^{23} is C_1 alkyl, R^{24} is selected from the group consisting of -H and C_1-C_6 alkyl, wherein when R^{24} is C_1-C_6 alkyl, R^{24} is optionally substituted by one or more moieties selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl, R^{25} is selected from the group consisting of -H, alkyl, and alkoxy, and R^{26} is selected from the group consisting of -H, -OH, alkyl, alkoxy, -C(O)-R^{38}, -C(O)-O-R^{39}, and -C(O)-S-R^{40}; wherein when R^{25} and R^{26} independently are alkyl or alkoxy, R^{25} and R^{26} independently are optionally substituted with one or more moieties selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl; or R^{25} is -H; and R^{26} is selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl, R^{27}, R^{28}, R^{29}, R^{30}, R^{31}, R^{32}, R^{33}, R^{34}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, and R^{40}

independently are selected from the group consisting of -H and alkyl, wherein alkyl is optionally substituted by one or more moieties selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein when any of R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, $R19^{9}$, R^{20}, R^{21}, R^{22}, R^{23}, R^{24}, R^{25}, R^{26}, R^{27}, R^{28}, R^{29}, R^{30}, R^{31}, R^{32}, R^{33}, R^{34}, R^{35} R^{36}, R^{37}, R^{38}, R^{39}, and R^{40} independently is a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclyl, aryl, and heteroaryl, then the moiety is optionally substituted by one or more substituent selected from the group consisting of -OH, alkoxy, and halogen;

and wherein the compound is selected from the group consisting of:



S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine, dihydrochloride;



2-[[[2-[(1-Iminoethyl)amino]ethyl]thio]methyl]-*O*-methyl-D-serine, dihydrochloride;



S-[2-[(1-Iminoethyl)amino]ethyl]-2-ethyl-L-cysteine, dihydrochloride;



2-[[[[2-(1-Iminoethyl)amino]ethyl]thio]methyl]-D-valine, dihydrochloride;



S-[2-(1-Iminoethylamino)ethyl]-2-methyl-(D/L)-cysteine, bistrifluoroacetate;



(2*R*)-2-Amino-3[[2-[(1-iminoethyl)amino]ethyl]sulfinyl]-2-methylpropanoic acid, dihydrochloride; and



(2*R*)-2-Amino-3[[2-[(1-iminoethyl)amino]ethyl]sulfonyl]-2-methylpropanoic acid dihydrochloride,

~~a compound represented by Formula III~~



III

~~wherein:~~

~~R^{41} is H or methyl; and~~

~~R^{42} is H or methyl;~~

~~a compound of formula IV~~



~~IV;~~

~~a compound of Formula V:~~



~~V~~

~~wherein:~~

~~R^{43} is selected from the group consisting of hydrogen, halo, C_1-C_5 alkyl and C_1-C_5 alkyl substituted by alkoxy or one or more halo;~~

~~R^{44} is selected from the group consisting of hydrogen, halo, C_1-C_5 alkyl and C_1-C_5 alkyl substituted by alkoxy or one or more halo;~~

~~R^{45} is C_1-C_5 alkyl or C_1-C_5 alkyl be substituted by alkoxy or one or more halo;~~

~~a compound of Formula VI:~~



~~VI~~

~~wherein:~~

~~R^{46} is C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo;~~

~~a compound of Formula VII~~



VII

wherein:

R^{47} is selected from the group consisting of hydrogen, halo, C_1-C_5 alkyl and C_1-C_5 alkyl substituted by alkoxy or one or more halo;

R^{48} is selected from the group consisting of hydrogen, halo, C_1-C_5 alkyl and C_1-C_5 alkyl substituted by alkoxy or one or more halo;

R^{49} is C_1-C_5 alkyl or C_1-C_5 alkyl be substituted by alkoxy or one or more halo;

a compound of Formula VIII



VIII

wherein:

R^{50} is C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo;

a compound of formula IX



~~IX~~

~~wherein:~~

~~R^{50} is selected from the group consisting of hydrogen, halo, and C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo;~~

~~R^{51} is selected from the group consisting of hydrogen, halo, and C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo;~~

~~R^{52} is C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo;~~

~~R^{53} is selected from the group consisting of hydrogen, halo, andC_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo; and~~

~~R^{54} is selected from the group consisting of halo and C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo;~~

~~a compound of formula X~~



~~X~~

~~wherein:~~

~~R^{55} is C_1-C_5 alkyl, said C_1-C_5 alkyl optionally substituted by halo or alkoxy, said alkoxy optionally substituted by one or more halo.~~

~~*a compound having the formula XI*~~



~~2S-amino-6-[(1-iminoethyl)amino]-N-(1H-tetrazol-5-yl) hexanamide, hydrate, dihydrochloride~~

~~XI~~

~~A compound of formula XII:~~



~~XII~~

~~wherein R^{79} is selected from C_{1-4} alkyl, C_{3-4} cycloalkyl, C_{1-4} hydroxyalkyl, and C_{1-4} haloalkyl;~~

~~a compound of Formula XIII, Formula XIV or Formula XV:~~



~~Formula XIII;~~



~~Formula XIV; or~~



~~Formula XV;~~

~~wherein:~~

~~A is $-R^{56}$, $-OR^{56}$, $-C(O)N(R^{56})R^{57}$, $-P(O)[N(R^{56})R^{57}]_2$, $-N(R^{56})C(O)R^{57}$, $-N(R^{76})C(O)OR^{56}$, $-N(R^{56})R^{76}$, $-N(R^{71})C(O)N(R^{56})R^{71}$, $-S(O)_tR^{56}$, $-SO_2NHC(O)R^{56}$, $-NHSO_2R^{77}$, $-SO_2NH(R^{56})H$, $-C(O)NHSO_2R^{77}$, and $-CH=NOR^{56}$;~~

~~each X, Y and Z are independently N or $C(R^{19})$;~~

~~each U is N or $C(R^{60})$, provided that U is N only when X is N and Z and Y are CR^{74};~~

~~V is $N(R^{59})$, S, O or $C(R^{59})H$;~~

~~Each W is N or CH;~~

~~Q is chosen from the group consisting of a direct bond, -C(O)-, -O-, $-C(=N-R^{56})-$, $S(O)_t$, and $-N(R^{61})-$;~~

~~m is zero or an integer from 1 to 4;~~

~~n is zero or an integer from 1 to 3;~~

~~q is zero or one;~~

~~r is zero or one, provided that when Q and V are heteroatoms, m, q, and r cannot all be zero;~~

~~when A is $-OR^{56}$, $N(R^{56})C(O)R^{57}$, $-N(R^{71})C(O)OR^{57}$, $-N(R^{56})R^{76}$, $-N(R^{71})C(O)N(R^{56})R^{71}$, $-S(O)_tR^{56}$ (where t is zero), or $-NHSO_2R^{77}$, n, q, and r~~

~~cannot all be zero; and when Q is a heteroatom and A is $-OR^{56}$, $N(R^{56})C(O)R^{57}$, $-N(R^{71})C(O)OR^{57}$, $-N(R^{56})R^{76}$, $N(R^{71})C(O)N(R^{56})R^{71}$, $-S(O)_tR^{56}$ (when t is zero), or $-NHSO_2R^{77}$, m and n cannot both be zero;~~

~~t is zero, one or two;~~



~~is an optionally substituted N-heterocyclyl;~~



~~is an optionally substituted carbocyclyl or optionally substituted N-heterocyclyl;~~

~~each R^{56} and R^{57} are independently chosen from the group consisting of hydrogen, optionally substituted C_1-C_{20} alkyl, optionally substituted cycloalkyl, -[C_0-C_8 alkyl]-R^{64}, -[C_2-C_8 alkenyl]-R^{64}, -[C_2-C_8 alkynyl]-R^{64}, -[C_2-C_8 alkyl]-R^{65} (optionally substituted by hydroxy), -[C_1-C_8]-R^{66} (optionally substituted by hydroxy), optionally substituted heterocyclyl;~~

~~or R^{56} and R^{57} together with the nitrogen atom to which they are attached is an optionally substituted N-heterocyclyl;~~

~~R^{58} is chosen from the group consisting of hydrogen, alkyl, cycloalkyl, optionally substituted aryl, haloalkyl, -[C_1-C_8 alkyl]-$C(O)N(R^{56})R^{57}$, -[C_1-C_8 alkyl]- $N(R^{56})R^{57}$, -[C_1-C_8 alkyl]-R^{63}, -[C_2-C_8 alk2yl]-R^{65}, -[C_1-C_8 alkyl]-R^{66}, and heterocyclyl (optionally substituted by one or more substitutents selected from the group consisting of halo, alkyl, alkoxy and imidazolyl);~~

~~or when Q is $-N(R^{58})$- or a direct bond to R^{58}, R^{58} may additionally be aminocarbonyl,~~

~~alkoxycarbonyl, alkylsulfonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl and $-C(=NR^{73})-NH_2$;~~

~~or $-Q-R^{58}$ taken together represents $-C(O)OH$, $-C(O)N(R^{56})R^{57}$ or~~



~~R^{59} is chosen from the group consisting of hydrogen, alkyl, aryl, aralkyl and cycloalkyl;~~

~~Provided that when A is $-R^{56}$ or $-OR^{56}$, R^{59} cannot be hydrogen, and when V is CH, R^{59} may additionally be hydroxy;~~

~~R^{60} is chosen from the group consisting of hydrogen, alkyl, aryl, aralkyl, haloalkyl,~~

~~optionally substituted aralkyl, optionally substituted aryl, $-OR^{71}$, $-S(O)_t-R^{71}$, $N(R^{71})R^{76}$, $N(R^{71})C(O)N(R^{56})R^{71}$, $N(R^{71})C(O)OR^{71}$, $N(R^{71})C(O)R^{71}$, $-[C_0-C_8$ alkyl]-$C(H)[C(O)R^{71}]_2$ and $-[C_0-C_8$ alkyl]-$C(O)N(R^{56})R^{71}$;~~

~~R^{61} is chosen from the group consisting of hydrogen, alkyl, cycloalkyl, $-[C_1-C_8$ alkyl]-R^{63}, $-[C_2-C_8]$alkyl]-R^{65}, $-[C_1-C_8$ alkyl]-R^{66}, acyl, $-C(O)R^{63}$, $-C(O)-[C_1-C_8$ alkyl]-R^{63}, alkoxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted aralkoxycarbonyl, alkylsulfonyl, optionally substituted aryl, optionally substituted heterocyclyl, alkoxycarbonylalkyl, carboxyalkyl, optionally substituted arylsulfonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, optionally substituted arylaminocarbonyl, aminosulfonyl, monoalkylaminosulfonyl dialkylaminosulfonyl, arylaminosulfonyl, arylsulfonylaminocarbonyl, optionally substituted N-heterocyclyl, $-C(=NH)-N(CN)R^{56}$, $-C(O)R^{78}-N(R^{56})R^{57}$, $-C(O)-N(R^{56})R^{78}-C(O)OR^{56}$;~~

~~each R^{63} and R^{64} are independently chosen from the group consisting of haloalkyl,~~
~~cycloalkyl, (optionally substituted with halo, cyano, alkyl or alkoxy),~~
~~carbocyclyl (optionally substituted with one or more substituents selected from the group consisting of halo, alkyl and alkoxy) and heterocyclyl (optionally substituted with alkyl, aralkyl or alkoxy);~~
~~each R^{65} is independently chosen from the group consisting of halo, alkoxy, optionally~~
~~substituted aryloxy, optionally substituted aralkoxy, optionally substituted $-S(O)_t-R^{77}$, acylamino, amino, monoalkylamino, dialkylamino,~~
~~(triphenylmethyl)amino, hydroxy, mercapto, alkylsulfonamido;~~
~~each R^{66} is independently chosen from the group consisting of cyano, di(alkoxy)alkyl,~~
~~carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl and dialkylaminocarbonyl;~~
~~each R^{67}, R^{68}, R^{69}, R^{70}, R^{72}, and R^{75} are independently hydrogen or alkyl;~~
~~each R^{71} is independently hydrogen, alkyl, optionally substituted aryl, optionally~~
~~substituted aralkyl or cycloalkyl;~~
~~R^{73} is hydrogen, NO_2, or toluenesulfonyl;~~
~~each R^{74} is independently hydrogen, alkyl (optionally substituted with hydroxy),~~
~~cyclopropyl, halo or haloalkyl;~~
~~each R^{76} is independently hydrogen, alkyl, cycloalkyl, optionally substituted aryl,~~
~~optionally substituted aralkyl, $-C(O)R^{77}$ or $-SO_2R^{77}$;~~
~~or R^{76} taken together with R^{56} and the nitrogen to which they are attached is an optionally~~
~~substituted N-heterocyclyl;~~

~~or R^{76} taken together with R^{74} and the nitrogen to which they are attached is an optionally~~
~~substituted N-heterocyclyl;~~
~~each R^{77} is independently alkyl, cycloalkyl, optionally substituted aryl or optionally~~
~~substituted aralkyl; and~~
~~R^{78} is an amino acid residue; and~~



~~PPA250~~

or a pharmaceutically acceptable salt or prodrug of any of said inducible nitric oxide synthase inhibitors.

Claim 23. (original) The method of Claim 22 wherein the antimicrobial compound comprises an antibiotic compound.

Claim 24 (original) The method of Claim 22 wherein the antimicrobial compound comprises at least one compound selected from the group consisting of the following: amoxicillin, clarithromycin, rifabutin, bismuth subsalicylate, metronidazole, and tetracycline.

Claim 25 (original) The method of Claim 22 further comprising administering to the subject an amount of an antisecretory compound or pharmaceutically acceptable salt thereof or prodrug thereof, wherein the amount of the inducible nitric oxide synthase selective inhibitor, the amount of the antibiotic compound and the amount of the antisecretory compound together

constitute an amount effective against the condition or disease of the gastrointestinal tract.

Claim 26 (original) The method of Claim 25 wherein the antisecretory compound comprises a proton-pump inhibitor.

Claim 27 (original) The method of Claim 26 wherein the antisecretory compound comprises omeprazole.

Claim 28 (original) The method of Claim 25 wherein the antisecretory compound comprises an H_2-receptor anatagonist.

Claim 29 (original) The method of Claim 28 wherein the antisecretory compound comprises ranitidine.

Claim 30. (original) The method of Claim 22 wherein the antimicrobial compound comprises a double anti-microbial composition consisting of a combination of two compounds selected from the group consisting of the following: amoxicillin, clarithromycin, rifabutin, bismuth subsalicylate, metronidazole, and tetracycline.

Claim 31 (original) The method of Claim 22 wherein the condition or disease of the gastrointestinal tract is selected from the group consisting of inflammatory bowel disease, Crohn's disease, ulcerative colitis, peptic ulcer disease, gastric ulceration, duodenal ulceration, esophagitis, gastritis, ileitis, colitis, gastroesophageal reflux disease, irritable bowel syndrome, irritable bowel syndrome, paralytic ileus and diarrhea.

Claim 32 (original) The method of Claim 22 wherein the condition or disease of the gastrointestinal tract is inflammatory bowel disease.

Claim 33 (original) The method of claim 22 wherein the condition or disease of the gastrointestinal tract is Crohn's disease.

Claim 34 (original) The method of claim 22 wherein the condition or disease of the gastrointestinal tract is ulcerative colitis.

Claim 35 (original) The method of claim 22 wherein the condition or disease of the gastrointestinal tract is peptic ulcer disease.

Claim 36. (original) The method of claim 35 wherein the condition or disease of the gastrointestinal tract is gastric ulceration.

Claim 37 (currently amended) The method of claim ~~235~~ 22 wherein the condition or disease of the gastrointestinal tract is duodenal ulceration.

Claim 38 (original) The method of claim 22 wherein the condition or disease of the gastrointestinal tract is gastritis.

Claim 39 (original) The method of claim 22 wherein the condition or disease of the gastrointestinal tract is ileitis.

Claim 40 (original) The method of claim 22 wherein the condition or disease of the gastrointestinal tract is colitis.

Claim 41 (original) The method of claim 22 wherein the condition or disease of the gastrointestinal tract is esophagitis.

Claim 42 (original) The method of claim 22 wherein the condition or disease of the gastrointestinal tract is gastroesophageal reflux disease.

Claim 43 (original) The method of claim 22 wherein the condition or disease of the gastrointestinal tract is irritable bowel syndrome.

Respectfully submitted,

Pharmacia Corporation
Corporate Patent Department
P.O. Box 1027
Chesterfield, Missouri 63006

Philip B. Polster II
Reg. No. 43,864
(314) 274-9094
(314) 274-9095 (facsimile)